Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
September 2008
Features
Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications
Increased cost sharing by patients results in the reduced use of prescription drugs. A retrospective study by the authors found that diabetic patients did not adhere to their regimens, and thus did not meet target treatment goals, if they were required to pay part of the cost of their medications.
John Barron, PharmD; Peter Wahl, MLA, MS; Maxine Fisher, PhD; and Craig Plauschinat, PharmD, MPH
Health Care and Law
Vaccine Declinations Present New Challenges for Public Health
Immunizations can protect large numbers of people in a community — even those who have not been inoculated. However, the reluctance of growing numbers of people to receive vaccinations for themselves and their children raises the risk of reducing “herd immunity,” which can lead to widespread infection in a population.
Robert I. Field, JD, MPH, PhD
Commentary
Universal Health Care in America: Can the Massachusetts Model Work Nationwide?
Every citizen 18 years of age and older in Massachusetts is required to obtain health insurance. This article describes the state’s progress and discusses how it might influence proposals for health care reform offered by the two presidential candidates.
Miriam Reisman
Meeting Highlights
Digestive Disease Week and American Diabetes Association
Therapies covered include balsalazide (Colazal) and infliximab (Remicade) for ulcerative colitis; infliximab/methotrexate and certolizumab pegol (Cimzia) for Crohn’s disease; and glucose-lowering strategies, as well as a combination of sitagliptin (Januvia) and metformin (Glucophage), for diabetes.
Walter Alexander
Pharmaceutical Approval Update
Topics include clevidipine (Cleviprex) for reducing blood pressure; repaglinide/ metformin (PrandiMet) for improving glycemic control; and difluprednate ophthalmic emulsion (Durezol) for treating inflammation and pain after ocular surgery.
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
Eight Tech Trends
David Nash, MD, MBA, describes eight emerging technology trends that are transforming markets and businesses and may soon be coming to a P&T committee near you.
David Nash, MD, MBA
Medication Errors
The Truth about Hospital Formularies, Part 2
In part 2 of a two-part article, Matthew Grissinger, RPh, FASCP, explains how P&T committee members can be negatively influenced when they encounter myths and misconceptions about formularies.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Democrats Getting Their Medicare Ducks in a Row for Next Year
Stephen Barlas discusses how taxpayers might be able to save almost $90 million per year if a bill were passed to eliminate the inflated prices for Part D Medicare benefits.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
From Cleviprex to Xenazine, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Ixabepilone (Ixempra), a Therapeutic Option for Locally Advanced or Metastatic Breast Cancer
Dr. Egerton reviews ixabepilone (Ixempra) for metastatic or locally advanced breast cancer.
Nancy Egerton, PharmD, BCOP
